News

The amended agreement includes a reduction of future royalties payable to LG Life Sciences, an LG affiliate, at certain Factive (gemifloxacin mesylate) revenue levels in territories covered by

This investigator-sponsored trial marks an expansion by the company into a second form of cancer. The trial will test Argos’ RNA loaded autologous dendritic cell vaccine among patients

The phase I trial is a double-blind, placebo-controlled, single rising dose study designed to assess the safety and pharmacokinetics of INCB7839 in healthy volunteers. A phase I multiple

These trial results are expected to be included as part of an amendment to the new drug application for the methylphenidate transdermal system (MTS) product currently pending at

The phase II study results show that LymphoStat-B (belimumab) is safe and well tolerated, biologically active, and reduces the signs and symptoms of rheumatoid arthritis at a level

The trial met its primary endpoint of a greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo.

The decision to discontinue the clinical trials is based on the recommendations of two separate independent data and safety monitoring boards (DSMBs). The onercept (recombinant tumor necrosis factor

The study, published in the Journal of the American Medical Association (JAMA), represents one of the largest, most comprehensive clinical trials evaluating the use of medication for the

The study is being conducted under a cooperative R&D agreement (CRADA) between Cell Therapeutics Inc (CTI) and the US National Cancer Institute (NCI) and involves three of the